Literature DB >> 22187320

Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations.

A Moran1, C O'Hara, S Khan, L Shack, E Woodward, E R Maher, F Lalloo, D G R Evans.   

Abstract

The risks of cancers other than breast and ovarian amongst BRCA1 and BRCA2 mutation carriers are based on relatively few family based studies with the risk of specific cancers tested in population based samples of cancers from founder populations. We assessed risks of "other cancers" in 268 BRCA1 families and 222 BRCA2 families using a person years at risk analysis from 1975 to 2005. Cancer confirmations were overall higher than in previous family based studies at 64%. There was no overall increase in risk for BRCA1 carriers although oesophagus had a significant increased RR of 2.9 (95% CI 1.1-6.0) and stomach at 2.4 (95% CI 1.2-4.3), these were based mainly on unconfirmed cases. For BRCA2 increased risks for cancers of the pancreas (RR 4.1, 95% CI 1.9-7.8) and prostate (RR 6.3, 95% CI 4.3-9.0) and uveal melanoma (RR 99.4, 95% CI 11.1-359.8) were confirmed. Possible new associations with oesophagus (RR 4.1, 95% CI 1.9-7.8) and stomach (RR 2.7, 95% CI 1.3-4.8) were detected but these findings should be treated with caution due to lower confirmation rates. In contrast to previous research a higher risk of prostate cancer was found in males with mutations in the BRCA2 OCCR region. The present study strengthens the known links between BRCA2 and pancreatic and prostate cancer, but throws further doubt onto any association with BRCA1. New associations with upper gastro-intestinal malignancy need to be treated with caution and confirmed by large prospective studies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22187320     DOI: 10.1007/s10689-011-9506-2

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  27 in total

1.  The accuracy of diagnoses as reported in families with cancer: a retrospective study.

Authors:  F S Douglas; L C O'Dair; M Robinson; D G Evans; S A Lynch
Journal:  J Med Genet       Date:  1999-04       Impact factor: 6.318

2.  Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies.

Authors:  A C Antoniou; P D P Pharoah; S Narod; H A Risch; J E Eyfjord; J L Hopper; H Olsson; O Johannsson; A Borg; B Pasini; P Radice; S Manoukian; D M Eccles; N Tang; E Olah; H Anton-Culver; E Warner; J Lubinski; J Gronwald; B Gorski; H Tulinius; S Thorlacius; H Eerola; H Nevanlinna; K Syrjäkoski; O-P Kallioniemi; D Thompson; C Evans; J Peto; F Lalloo; D G Evans; D F Easton
Journal:  J Med Genet       Date:  2005-07       Impact factor: 6.318

3.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.

Authors:  J P Struewing; P Hartge; S Wacholder; S M Baker; M Berlin; M McAdams; M M Timmerman; L C Brody; M A Tucker
Journal:  N Engl J Med       Date:  1997-05-15       Impact factor: 91.245

4.  Identification of the breast cancer susceptibility gene BRCA2.

Authors:  R Wooster; G Bignell; J Lancaster; S Swift; S Seal; J Mangion; N Collins; S Gregory; C Gumbs; G Micklem
Journal:  Nature       Date:  1995 Dec 21-28       Impact factor: 49.962

5.  Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13.

Authors:  D F Easton; L Steele; P Fields; W Ormiston; D Averill; P A Daly; R McManus; S L Neuhausen; D Ford; R Wooster; L A Cannon-Albright; M R Stratton; D E Goldgar
Journal:  Am J Hum Genet       Date:  1997-07       Impact factor: 11.025

6.  Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer.

Authors:  E Warner; W Foulkes; P Goodwin; W Meschino; J Blondal; C Paterson; H Ozcelik; P Goss; D Allingham-Hawkins; N Hamel; L Di Prospero; V Contiga; C Serruya; M Klein; R Moslehi; J Honeyford; A Liede; G Glendon; J S Brunet; S Narod
Journal:  J Natl Cancer Inst       Date:  1999-07-21       Impact factor: 13.506

7.  BRCA1 and BRCA2 families and the risk of skin cancer.

Authors:  Ophira M Ginsburg; Charmaine Kim-Sing; William D Foulkes; Parviz Ghadirian; Henry T Lynch; Ping Sun; Steven A Narod
Journal:  Fam Cancer       Date:  2010-12       Impact factor: 2.375

8.  Is there any relationship between BRCA1 gene mutation and pancreatic cancer development?

Authors:  Małgorzata Lawniczak; Alicja Gawin; Andrzej Białek; Jan Lubiński; Teresa Starzyńska
Journal:  Pol Arch Med Wewn       Date:  2008-11

9.  Contribution of germline mutations in BRCA2, P16(INK4A), P14(ARF) and P15 to uveal melanoma.

Authors:  Nicholas Hearle; Bertil E Damato; Jane Humphreys; Julie Wixey; Helen Green; Joanne Stone; Douglas F Easton; Richard S Houlston
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-02       Impact factor: 4.799

Review 10.  Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature.

Authors:  Alexander Liede; Beth Y Karlan; Steven A Narod
Journal:  J Clin Oncol       Date:  2004-02-15       Impact factor: 44.544

View more
  103 in total

Review 1.  Familial pancreatic cancer--current knowledge.

Authors:  Detlef K Bartsch; Thomas M Gress; Peter Langer
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-06-05       Impact factor: 46.802

Review 2.  Familial pancreatic cancer--status quo.

Authors:  Volker Fendrich; Peter Langer; Detlef K Bartsch
Journal:  Int J Colorectal Dis       Date:  2013-08-16       Impact factor: 2.571

3.  Germline RAD51B truncating mutation in a family with cutaneous melanoma.

Authors:  Karin A W Wadt; Lauren G Aoude; Lisa Golmard; Thomas V O Hansen; Xavier Sastre-Garau; Nicholas K Hayward; Anne-Marie Gerdes
Journal:  Fam Cancer       Date:  2015-06       Impact factor: 2.375

4.  Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma.

Authors:  Peter A Johansson; Vaishnavi Nathan; Lauren M Bourke; Jane M Palmer; Tongwu Zhang; Judith Symmons; Madeleine Howlie; Ann-Marie Patch; Jazlyn Read; Elizabeth A Holland; Helen Schmid; Sunil Warrier; William Glasson; Veronica Höiom; Karin Wadt; Göran Jönsson; Håkan Olsson; Christian Ingvar; Graham Mann; Kevin M Brown; Nicholas K Hayward; Antonia L Pritchard
Journal:  Melanoma Res       Date:  2019-10       Impact factor: 3.599

5.  High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions.

Authors:  Aimee L Lucas; Reena Shakya; Marla D Lipsyc; Elana B Mitchel; Sheila Kumar; Caroline Hwang; Liyong Deng; Catherine Devoe; John A Chabot; Matthias Szabolcs; Thomas Ludwig; Wendy K Chung; Harold Frucht
Journal:  Clin Cancer Res       Date:  2013-05-08       Impact factor: 12.531

Review 6.  Clinical impact of tumour biology in the management of gastroesophageal cancer.

Authors:  Florian Lordick; Yelena Y Janjigian
Journal:  Nat Rev Clin Oncol       Date:  2016-03-01       Impact factor: 66.675

Review 7.  Risk of pancreatic cancer in breast cancer families from the breast cancer family registry.

Authors:  Evelina Mocci; Roger L Milne; Elena Yuste Méndez-Villamil; John L Hopper; Esther M John; Irene L Andrulis; Wendy K Chung; Mary Daly; Saundra S Buys; Nuria Malats; David E Goldgar
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-03-01       Impact factor: 4.254

8.  Evidence for predictive role of BRCA1 and bTUBIII in gastric cancer.

Authors:  Vladimir M Moiseyenko; Nikita M Volkov; Evgeny N Suspistin; Grigoriy A Yanus; Aglaya G Iyevleva; Ekatherina Sh Kuligina; Alexandr V Togo; Alexandr V Kornilov; Alexandr O Ivantsov; Evgeny N Imyanitov
Journal:  Med Oncol       Date:  2013-03-27       Impact factor: 3.064

9.  The role of germline mutations in the BRCA1/2 and mismatch repair genes in men ascertained for early-onset and/or familial prostate cancer.

Authors:  Sofia Maia; Marta Cardoso; Paula Paulo; Manuela Pinheiro; Pedro Pinto; Catarina Santos; Carla Pinto; Ana Peixoto; Rui Henrique; Manuel R Teixeira
Journal:  Fam Cancer       Date:  2016-01       Impact factor: 2.375

Review 10.  PALB2: the hub of a network of tumor suppressors involved in DNA damage responses.

Authors:  Jung-Young Park; Fan Zhang; Paul R Andreassen
Journal:  Biochim Biophys Acta       Date:  2014-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.